Reviewing Eloxx Pharmaceuticals Inc. (ELOX)’s and Radius Health Inc. (NASDAQ:RDUS)’s results

Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) and Radius Health Inc. (NASDAQ:RDUS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals Inc. 5 0.00 21.81M -1.47 0.00
Radius Health Inc. 26 -0.23 43.47M -4.45 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Eloxx Pharmaceuticals Inc. and Radius Health Inc.


Table 2 has Eloxx Pharmaceuticals Inc. and Radius Health Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals Inc. 481,456,953.64% -107.1% -88.5%
Radius Health Inc. 169,871,043.38% -252.8% -65.9%

Volatility & Risk

Eloxx Pharmaceuticals Inc. is 71.00% more volatile than S&P 500 because the company has a beta of 1.71. Competitively, Radius Health Inc. is 8.00% less volatile than S&P 500, because of the 0.92 beta.


Eloxx Pharmaceuticals Inc.’s Current Ratio is 6.6 while its Quick Ratio is 6.6. On the competitive side is, Radius Health Inc. which has a 5.2 Current Ratio and a 5 Quick Ratio. Eloxx Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Radius Health Inc.

Analyst Ratings

Ratings and Recommendations for Eloxx Pharmaceuticals Inc. and Radius Health Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eloxx Pharmaceuticals Inc. 0 0 0 0.00
Radius Health Inc. 0 1 2 2.67

On the other hand, Radius Health Inc.’s potential upside is 59.16% and its consensus target price is $34.33.

Institutional and Insider Ownership

The shares of both Eloxx Pharmaceuticals Inc. and Radius Health Inc. are owned by institutional investors at 50.1% and 0% respectively. Insiders held 0.4% of Eloxx Pharmaceuticals Inc. shares. On the other hand, insiders held about 0.3% of Radius Health Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eloxx Pharmaceuticals Inc. -0.12% -17.66% -28.55% -29.23% -46.1% -32.06%
Radius Health Inc. -5.46% -12.52% 4.58% 18.69% -11.25% 30.14%

For the past year Eloxx Pharmaceuticals Inc. had bearish trend while Radius Health Inc. had bullish trend.


Eloxx Pharmaceuticals Inc. beats Radius Health Inc. on 6 of the 11 factors.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.